Proove Biosciences Will Be Exhibiting at the 21st Annual Napa Pain Conference

Proove Biosciences will exhibit their industry leading research on how genetic factors play a role in prescription addiction and how their technology has been helping increase safety in workers’ compensation treatment

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
"As the commercial leader in personalized pain medicine research and genetic testing, Proove Biosciences is committed to helping patients manage and treat their pain" - Brian Meshkin, CEO, Proove Biosciences

IRVINE, CA and ANNAPOLIS JUNCTION, MD (PRWEB) September 04, 2014

Proove Biosciences, the commercial and research leader in personalized medicine, will be attending the 21st Annual Napa Pain Conference, September 5th-7th, at the Meritage Conference Center. Proove will specifically be presenting research conducted through their proprietary PILL II Study.

The PILL II study examined the prevalence of genetic variations in a population of chronic pain patients who were taking prescription opioids. Proove researchers found that there is in fact a greater prevalence of these genetic variations in the study group vs. the control population.

The Napa Pain Conference is a leading CME pain management conference that traditionally presents new data and best practices in pain therapies. The conference is designed to provide significant educational opportunity to everyone, regardless of position, or role in the pain management and pain treatment industry.

Proove Biosciences’ genetic testing has allowed pain management physicians to better assess their patient’s needs by analyzing how they will react to specific treatments, and help physicians decide if there are better alternatives to consider,” stated Brian Meshkin, CEO of Proove Biosciences.

The nationally acclaimed annual conference is the premier event for the study of pain diagnosis and treatment. Regarding opioids and addiction, the conference aims to provide an understanding of current medical treatment; review current processes for patients at risk for aberrant behaviors related to prescription drug abuse; discuss strategies to enhance safety; and increase awareness of best practices to help reduce and prevent opioid over-prescribing.

“As the commercial leader in personalized pain medicine research and genetic testing, Proove Biosciences is committed to helping patients manage and treat their pain in the most efficient and safest way possible,” stated Meshkin. “This is only possible by truly understanding how the patient will react to treatment based off their individual genetic factors, and we are excited to share how Proove has been helping achieve this at the 21st Annual Napa Pain Conference.”

About Proove Biosciences

Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe such knowledge can be provided by genetic testing: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.

Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).


Contact